NERV Minerva Neurosciences
- 2.4415
- -0.0785-3.12%
Minerva Neurosciences News
Minerva Neurosciences Price Target Cut to $7.00/Share From $11.00 by HC Wainwright & Co.
Minerva Neurosciences Price Target Cut to $7.00/Share From $11.00 by HC Wainwright & Co.
Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.
Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $7
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and lowers the price target from $11 to $7.
Minerva Neurosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 197.87% HC Wainwright & Co. $11 → $7 Maintains Neutral 02/27/2024 368.09% HC Wainwright & Co. →
Express News | Minerva Neurosciences, Inc. : H.c. Wainwright Cuts Target Price to $7 From $11
Express News | Minerva Neurosciences Inc - Qtrly Net Loss per Share of $1.13 Basic and Diluted
Express News | Minerva Neurosciences Inc - Is in Discussions With FDA Regarding Issues and Clinical Deficiencies Raised in the Crl for Roluperidone
Express News | Minerva Neurosciences Q1 EPS USD -1.13
Express News | Minerva Neurosciences Q1 Net Income USD -8.569 Million
Express News | Minerva Neurosciences Q1 Operating Expenses USD 6.682 Million
Express News | Minerva Neurosciences Q1 Income From Operations USD -6.682 Million
Express News | Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Express News | Minerva Neurosciences Inc - on April 10, Got Notice From Nasdaq That Company Was Not in Compliance With Nasdaq’s Listing Rule
Top Midday Decliners
Minerva Neurosciences (NERV) said the US Food and Drug Administration rejected its new drug application for roluperidone, an investigational treatment for negative symptoms of schizophrenia, citing "c
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index shedding 0.2% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose 1.1
Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data
Minerva Neurosciences Inc (NASDAQ:NERV) shares are trading lower after the FDA issued a Complete Response Letter (CRL) to the company's marketing application for roluperidone for the treatment of nega
BBAI, CTMX and STRC Among Mid-day Movers
Express News | HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $11 Price Target
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersJanux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutics (NASDAQ:VKTX) shares
Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints
Analysis
Price Target
No Data
